Company Profile

ASDDR LLC
Profile last edited on: 1/5/2018      CAGE: 7F6L2      UEI: FJ4ZV9YC2HK3

Business Identifier: NO Business Identifier is currently available for this company.
Year Founded
2015
First Award
2017
Latest Award
2018
Program Status
Active
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

9 Vassar Drive
Getzville, NY 14068
   N/A
   N/A
   www.asddr-us.com
Location: Single
Congr. District: 26
County: Erie

Public Profile

Building on their earlier determination at the Universityof Buffalo re. how to reverse certain disruptions of neuronal communication that resulted in the rescue of autism-like behaviors in an animal model, principals of ASDDR LLC discovered how to reverse certain disruptions of neuronal communication stemming from the deletion of the Shank3 gene, which results in autism-like behaviors in an animal model. The UB scientists found that the disruption of this neuronal communication results from the dysregulation of actin filaments, a kind of cellular "highway" in the brain's prefrontal cortex, the command center for high-level executive functions and a key region implicated in ASD. The Investigators further found that once the expression or activity of certain actin regulators was returned to normal -- alloweing for the normal trafficking and functioning of important neuronal receptors - social behaviors in these mice could be restored. Subsequent research is focusing on novel therapeutic strategies for autism by finding an effective treatment for patients with ASD who have genetic deletion or loss-of-function mutations of Shank3 and studying how these findings might be applied to treating ASD when other genetic mutations are implicated.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
1-4

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2018 2 NIH $771,464
Project Title: Discovery of Novel Drugs for Autism

Key People / Management

  Martina Tsai

  Zhen Yan